All AbMole products are for research use only, cannot be used for human consumption.
PCI-24781 is a broad-spectrum phenyl hydroxamic acid HDAC inhibitor with chemotherapy for the treatment of soft tissue sarcoma. PCI-24781 exhibited significant anti-STS proliferative activity in vitro, inducing S phase depletion, G(2)/M cell cycle arrest, and increasing apoptosis. Superior effects were seen when combined with chemotherapy. A PCI-24781-induced reduction in Rad51, a major mediator of DNA double-strand break homologous recombination repair, was shown and may be a mechanism underlying PCI-24781 chemosensitization. We showed that PCI-24781 transcriptionally represses Rad51 through an E2F binding-site on the Rad51 proximal promoter. Although single-agent PCI-24781 had modest effects on STS growth and metastasis, marked inhibition was observed when combined with chemotherapy.
*The compound is unstable in solutions, freshly prepared is recommended
 |
Source | Genet Mol Biol (2014). Figure 2. PCI-24781 |
| Method | cell apoptosis assay | |
| Cell Lines | malignant glioma cells | |
| Concentrations | 0.5 or 1 μM | |
| Incubation Time | 48 h | |
| Results | Similarly, PCI-24781 also induced apoptosis in a concentration-dependent manner |
| Cell Experiment | |
|---|---|
| Cell lines | HCT-116, DLD-1, HCT-15, MCF-7, BT-549, NCI-H226, CWR-22RV1, NCI-PC3, SKOV-3, OVCAR-3 and HUVEC cells line |
| Preparation method | Cell Proliferation Assay Ten tumor cell lines and HUVEC were cultured for at least two doubling times, and growth was monitored at the end of compound exposure using an Alamar blue (Biosource, Camarillo, CA) fluorometric cell proliferation assay as previously described (13). The compound was assayed in triplicate wells in 96-well plates at nine concentrations using half-log intervals ranging from 0.0015 to 10 μmol/L. The final DMSO concentration in each well was 0.15%. The concentration required to inhibit cell growth by 50% (GI50%) and 95% confidence intervals were estimated from nonlinear regression using a four-parameter logistic equation. |
| Concentrations | 0.15 to 3.09 μ M |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | HCT116 and DLD-1 tumor -bearing Female BALB/c nu/nu mice |
| Formulation | 20% HP-β-cyclodextrin in water |
| Dosages | q.d. × 4 per week |
| Administration | i.v. |
| Molecular Weight | 397.42 |
| Formula | C21H23N3O5 |
| CAS Number | 783355-60-2 |
| Solubility (25°C) | DMSO 22 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related HDAC Products |
|---|
| Belinostat
Belinostat (PXD101) is a novel HDAC inhibitor with an IC50 of 27 nM. |
| CUDC-101
CUDC-101 is a potent multitargeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively. |
| Givinostat hydrochloride monohydrate
ITF2357 (Givinostat, Gavinostat) is a histone deacetylase inhibitor. The IC50 values for maize HDAC preparations HD2, HD-1B and HD-1A are 10, 7.5 and 16 nM respectively. |
| Niltubacin
Niltubacin, as an inactive derivative of Tubacin, is a highly potent and selective, reversible cell-permeable inhibitor of HDAC6. |
| Tubacin
Tubacin (Tubulin Acetylation Inducer) is a highly potent and selective, reversible cell-permeable inhibitor of HDAC6 with IC50 of 0.004µM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
